/CTNM
CTNM Stock - Contineum Therapeutics, Inc. Class A Common Stock
Healthcare|BiotechnologyNASDAQ
$11.74+3.07%
+$0.35 (+3.07%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+59.0%upside
Target: $18.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CTNM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.62 – $11.86
TARGET (TP)$18.67
STOP LOSS$10.80
RISK/REWARD1:7.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.25
52W High$15.25
52W Low$3.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | $50.00M | N/A | N/A |
| Gross Profit | $-258,000 | $50.00M | $-329,000 | N/A |
| Gross Margin | N/A | 100.0% | N/A | N/A |
| Operating Income | $-50,894,000 | $-16,077,000 | $-22,720,000 | $-28,647,000 |
| Net Income | $-42,258,000 | $22.72M | $-24,253,000 | $-29,001,000 |
| Net Margin | N/A | 45.4% | N/A | N/A |
| EPS | $-2.18 | $0.90 | $-0.97 | $-1.15 |
Company Overview
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$26
Average Target
↑ 124.3% Upside
Now
$20
Low
$26
Average
$32
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Leerink Partners | Initiation | Outperform | $22 |
| September 25th 2025 | Leerink Partners | Initiation | Outperform | $20 |
| June 20th 2025 | William Blair | Initiation | Outperform | - |
| October 22nd 2024 | Robert W. Baird | Initiation | Outperform | $32 |
| April 30th 2024 | RBC Capital Mkts | Initiation | Outperform | $30 |
| April 30th 2024 | Morgan Stanley | Initiation | Overweight | $25 |
| April 30th 2024 | Stifel | Initiation | Buy | $29 |
Earnings History & Surprises
CTNMBeat Rate
29%
Last 7 quarters
Avg Surprise
-101.0%
EPS vs Estimate
Beats / Misses
2/5
Last 12 quarters
Latest EPS
$-0.45
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
-671.7%
$-3.55vs$-0.46
Q3 24
-11.4%
$-0.39vs$-0.35
Q4 24
+2.4%
$-0.40vs$-0.41
Q1 25
-27.3%
$-0.56vs$-0.44
Q2 25
-10.7%
$-0.62vs$-0.56
Q3 25
-10.7%
$-0.62vs$-0.56
Q4 25
+22.4%
$-0.45vs$-0.58
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $-0.53 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.58 | $-0.45 | +22.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.56 | $-0.62 | -10.7% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.56 | $-0.62 | -10.7% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.44 | $-0.56 | -27.3% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.35 | $-0.39 | -11.4% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.46 | $-3.55 | -671.7% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-0.31 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.25 | — | — |
Q2 2023 | Jun 30, 2023 | — | $1.62 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.19 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.30 | — | — |
Latest News
Contineum Therapeutics shares are trading lower after the company announced the pricing of its $90 million million public offering of 7,346,938 shares at $12.25 per share.
📉 NegativeBenzinga•Dec 12, 2025, 02:21 PM
Reported Earlier, Contineum Therapeutics Prices Upsized $90.0M Public Offering Of 7,346,938 Class A Common Shares At $12.25 Per Share
➖ NeutralBenzinga•Dec 12, 2025, 08:01 AM
Contineum Therapeutics stock drops as company prices upsized $90 million offering
📉 NegativeSeeking Alpha•Dec 12, 2025, 06:55 AM
Contineum Therapeutics shares are trading lower after the company announced a proposed $75 million public offering of Class A common shares.
📉 NegativeBenzinga•Dec 11, 2025, 09:16 PM
Contineum Therapeutics Announces Proposed $75M Public Offering Of Class A Common Shares
➖ NeutralBenzinga•Dec 11, 2025, 09:09 PM
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 24, 2025, 02:43 PM
RBC Capital Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $22
➖ NeutralBenzinga•Nov 21, 2025, 02:35 PM
Contineum falls after missing main goals in multiple sclerosis trial
📉 NegativeSeeking Alpha•Nov 21, 2025, 02:17 PM
Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VISTA trial of PIPE-307 did not meet its primary or secondary efficacy endpoints.
📉 NegativeBenzinga•Nov 21, 2025, 02:13 PM
Market-Moving News for November 21st
➖ NeutralBenzinga•Nov 21, 2025, 12:16 PM•Also: ,
Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VISTA trial of PIPE-307 did not meet its primary or secondary efficacy endpoints.
📉 NegativeBenzinga•Nov 20, 2025, 09:36 PM
Trading Halt: Halt status updated at 4:20:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 20, 2025, 09:20 PM
Contineum Therapeutics Announces Phase 2 PIPE-307 VISTA Trial Did Not Meet Prespecified Primary Or Secondary Efficacy Endpoints
📉 NegativeBenzinga•Nov 20, 2025, 09:08 PM
Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 20, 2025, 09:01 PM
Contineum Therapeutics Q3 EPS $(0.45) Beats $(0.60) Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:51 PM
Leerink Partners Initiates Coverage On Contineum Therapeutics with Outperform Rating, Announces Price Target of $20
📈 PositiveBenzinga•Sep 25, 2025, 11:21 AM
Contineum Therapeutics Reports Topline Data From Phase 1b Positron Emission Tomography Trial Of PIPE-791; PIPE-791 Achieved High LPA1 Brain Receptor Occupants, Showed Safety And Tolerability Profile Consistent With Previous Clinical Studies
📈 PositiveBenzinga•Sep 18, 2025, 12:10 PM
Contineum Therapeutics shares are trading higher after Morgan Stanley raised its price target on the stock from $20 to $21.
📈 PositiveBenzinga•Aug 18, 2025, 05:32 PM
Morgan Stanley Maintains Overweight on Contineum Therapeutics, Raises Price Target to $21
📈 PositiveBenzinga•Aug 18, 2025, 01:10 PM
Frequently Asked Questions about CTNM
What is CTNM's current stock price?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is currently trading at $11.74 per share. The stock has moved +3.07% today.
What is the analyst price target for CTNM?
The average analyst price target for CTNM is $18.67, based on 1 analyst.
What sector is Contineum Therapeutics, Inc. Class A Common Stock in?
Contineum Therapeutics, Inc. Class A Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CTNM's market cap?
Contineum Therapeutics, Inc. Class A Common Stock has a market capitalization of $0.34 billion, making it a small-cap company.
Does CTNM pay dividends?
No, Contineum Therapeutics, Inc. Class A Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CADL
Candel Therapeutics, Inc.
$5.57
Mkt Cap: $0.3B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to CTNM for comparison